Navigation Links
BrainStorm CEO to Present at the Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum
Date:3/22/2017

HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 22, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide an update on new developments and a corporate overview at Sachs Associates 2nd Annual Neuroscience Biopartnering and Investment Forum, being held on March 27th at the New York Academy of Sciences.

Neuroscience Biopartnering and Investment Forum Presentation Details Date:      

Monday, March 27Time:             

2:20pm Eastern TimeLocation:       

New York Academy of Sciences, 7 World Trade Center

About the Annual Neuroscience BioPartnering & Investment ForumThe 2nd Annual Neuroscience BioPartnering & Investment Forum to take place on 27th of March at the New York Academy of Sciences. It will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. For more information, refer to http://www.sachsforum.com/2nbpi-about.html

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo.  For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTSMedia:
Uri Yablonka
Brainstorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-ceo-to-present-at-the-sachs-associates-2nd-annual-neuroscience-biopartnering-and-investment-forum-300427336.html


'/>"/>
SOURCE BrainStorm Cell Therapeutics Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BrainStorm Cell Therapeutics Reports First Quarter 2016 Financial Results And Provides Corporate Update
2. BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
3. BrainStorm Hosting Conference Call to Update Shareholders on Important Developments
4. BrainStorm Awarded Additional $735,000 Non-Dilutive Grant for 2015 from Israels Office of the Chief Scientist
5. BrainStorm Cell Therapeutics Reports Third Quarter 2015 Financial Results And Provides Corporate Update
6. BrainStorm Cell Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa
7. BrainStorm Cell Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
8. BrainStorm Cell Therapeutics to Report Second Quarter 2015 Financial Results on Thursday, August 13
9. BrainStorm Cell Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14
10. BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israels Chief Scientist Office
11. BrainStorm Cell Therapeutics to Report Third Quarter 2014 Financial Results on Thursday, November 13
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/7/2018)... ... , ... Since September of this year, stem cell biotechnology ... tissue stem cell counting problem in stem cell medicine and the stem cell ... with new educational publications and presentations at clinical trial supply conferences, at meetings ...
(Date:11/6/2018)... ... November 06, 2018 , ... Crucial ... trial data collection and management. TrialKit ™, an eClinical platform, has incorporated ... can quickly and easily sign in to the app via facial recognition or ...
(Date:11/5/2018)... (PRWEB) , ... November 05, 2018 , ... ... and telemedicine company backed by Siemens Healthineers and several healthcare VC firms announces ... radiology solution and making a history by purchasing tokens and obtaining its first ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades has completed a ... (TAL) effector code technology for applications in advancing research in epigenetic technology. ... its discovery in 2009, the efficacy of TAL effector-based DNA targeting has been ...
Breaking Biology Technology:
(Date:12/5/2018)... FRANCISCO (PRWEB) , ... December 03, 2018 , ... ... of Dr. Amir Zarrinpar, MD, PhD, assistant professor in the Division of Gastroenterology ... Diego Medical Center, to its Medical Advisory Board. Joining the board of leading ...
(Date:12/5/2018)... ... December 04, 2018 , ... ... much-anticipated launch of their 100-liter (26 gallon) SAFEthread Drum. The 100-liter SAFEthread ... 2017, which brought a much-needed modern redesign to the plastic drums being used ...
(Date:11/29/2018)... Pa. (PRWEB) , ... November 29, 2018 , ... ... investment in Semba Biosciences with the intention of acquiring full ownership. The transaction ... Participation Agreement was executed on November 14, 2018. “We are extremely pleased to ...
Breaking Biology News(10 mins):